Piper Sandler lowered the firm’s price target on Immunome (IMNM) to $21 from $23 and keeps an Overweight rating on the shares after the ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Brooke was only three years old when she first learned about desmoid tumors. “My mother had six or seven,” she recalls.

In a report released yesterday, Alec Stranahan from Bank of America Securities reiterated a Buy rating on Springworks Therapeutics (SWTX ...

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

SpringWorks Therapeutics (SWTX) announced that data from the pivotal, Phase 2b ReNeu trial of mirdametinib, an ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

Australian inventor Lawrence Hargrave created history when he was lifted off the ground in a flying device he created in 1894. Now, 130 years later, he is remembered as a generous pioneer whose ...

Encouraging results from Phase 1/2 study of mirdametinib in pediatric patients with low-grade glioma also to be presented in oral session at SNO – STAMFORD, Conn., (GLOBE NEWSWIRE) -- SpringWorks ...

Nov. 12, 2024 — Researchers have found that the way DNA is packaged in cells can directly impact how fast DNA itself is copied during cell division. They discovered that DNA packaging sends ...